TI
ATXS

Trexquant Investment’s Astria Therapeutics ATXS Stock Holding History

Trexquant Investment’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,409
Closed -$229K – 1575
2025
Q3 		$229K Buy
+31,409
New +$213K ﹤0.01% 1472
2024
Q1 		– Sell
-53,204
Closed -$409K – 1424
2023
Q4 		$409K Buy
+53,204
New +$294K 0.01% 1148
2023
Q1 		– Sell
-15,475
Closed -$230K – 1431
2022
Q4 		$230K Buy
+15,475
New +$160K 0.01% 1194

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's ATXS Position: Q4 2025 in Review

Trexquant Investment sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 31,409 shares — an estimated $229K sold.

Trexquant Investment first reported a position in ATXS in Q4 2022 and held it in 3 quarters. The position peaked at $409K in Q4 2023. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Trexquant Investment reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Trexquant Investment sold 31,409 Astria Therapeutics shares in Q4 2025, an estimated $229K.
  • Trexquant Investment first reported a position in Astria Therapeutics in Q4 2022 and held it in 3 quarters.
  • Trexquant Investment's Astria Therapeutics position peaked at $409K in Q4 2023.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.